Consecutively, new phase 1 and 2 clinical trials evaluate the efficacy of bi- or tri-specific antibodies in locally advanced or metastatic BC patients, through for example HER2/CD3 bispecific target (NCT03448042), NK cell/T-cell/HER2 tri-specific target (NCT04143711), HER2/PD-1 bi-specific target (NCT04162327), or two non-overlapping domains of HER2 target (NCT04224272). The gene discussed is ERBB2; the disease is breast cancer.